JP2009520696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009520696A5 JP2009520696A5 JP2008546020A JP2008546020A JP2009520696A5 JP 2009520696 A5 JP2009520696 A5 JP 2009520696A5 JP 2008546020 A JP2008546020 A JP 2008546020A JP 2008546020 A JP2008546020 A JP 2008546020A JP 2009520696 A5 JP2009520696 A5 JP 2009520696A5
- Authority
- JP
- Japan
- Prior art keywords
- pro
- arg
- gly
- glu
- leu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0206705A AT502987A1 (de) | 2005-12-23 | 2005-12-23 | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
| PCT/AT2006/000465 WO2007070899A2 (de) | 2005-12-23 | 2006-11-10 | Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009520696A JP2009520696A (ja) | 2009-05-28 |
| JP2009520696A5 true JP2009520696A5 (enExample) | 2009-12-24 |
Family
ID=37846035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008546020A Pending JP2009520696A (ja) | 2005-12-23 | 2006-11-10 | 出血性ショックおよびその続発症を治療するための製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7897574B2 (enExample) |
| EP (2) | EP2110136A3 (enExample) |
| JP (1) | JP2009520696A (enExample) |
| KR (1) | KR20080108221A (enExample) |
| CN (1) | CN101365477A (enExample) |
| AT (2) | AT502987A1 (enExample) |
| AU (1) | AU2006326890A1 (enExample) |
| CA (1) | CA2634026A1 (enExample) |
| DE (1) | DE502006004619D1 (enExample) |
| ES (1) | ES2331970T3 (enExample) |
| IL (1) | IL192349A0 (enExample) |
| NO (1) | NO20083191L (enExample) |
| RU (1) | RU2008130413A (enExample) |
| WO (1) | WO2007070899A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1987062B1 (en) * | 2006-02-23 | 2011-06-22 | Fibrex Medical Research & Development GmbH | Peptides and peptide derivatives as well as pharmaceutical compositions containing the same |
| WO2009039542A2 (en) * | 2007-09-24 | 2009-04-02 | Fibrex Medical Research & Development Gmbh | Methods of screening for compounds having anti- inflammatory activity and/or prevent / treat vascular leak |
| US20130324469A1 (en) * | 2010-12-09 | 2013-12-05 | The Brigham And Women's Hospital, Inc. | Fibrinogen and kidney damage |
| US20170112941A1 (en) * | 2015-10-13 | 2017-04-27 | Symic Ip, Llc | Ve-cadherin binding bioconjugate |
| JP7506364B2 (ja) * | 2019-10-24 | 2024-06-26 | 国立大学法人東海国立大学機構 | 慢性肺疾患／急性呼吸窮迫症候群の治療薬 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5997844A (en) * | 1991-02-08 | 1999-12-07 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| SI1341819T1 (sl) * | 2000-12-12 | 2006-10-31 | Fibrex Medical Res & Dev Gmbh | Uporaba fibrinskih/fibrinogenskih peptidov in proteinov za pripravo zdravila |
| US20080311103A1 (en) * | 2004-03-08 | 2008-12-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Anti-Inflammatory Peptides and Methods of Use Thereof |
| SI1691827T1 (sl) * | 2004-06-25 | 2010-01-29 | Fibrex Medical Res & Dev Gmbh | Uporaba peptidov, izvedenih iz Bbeta-verige človeškega fibrinogena, za zdravljenje šoka |
| AT414097B (de) | 2004-06-25 | 2006-09-15 | Petzelbauer Peter Dr | Pharmazeutische zubereitung zur behandlung von schock |
-
2005
- 2005-12-23 AT AT0206705A patent/AT502987A1/de not_active Application Discontinuation
-
2006
- 2006-11-10 AU AU2006326890A patent/AU2006326890A1/en not_active Abandoned
- 2006-11-10 CA CA002634026A patent/CA2634026A1/en not_active Abandoned
- 2006-11-10 EP EP09010282A patent/EP2110136A3/de not_active Withdrawn
- 2006-11-10 AT AT06804388T patent/ATE440282T1/de active
- 2006-11-10 KR KR1020087017988A patent/KR20080108221A/ko not_active Ceased
- 2006-11-10 WO PCT/AT2006/000465 patent/WO2007070899A2/de not_active Ceased
- 2006-11-10 DE DE502006004619T patent/DE502006004619D1/de active Active
- 2006-11-10 US US12/158,670 patent/US7897574B2/en not_active Expired - Fee Related
- 2006-11-10 ES ES06804388T patent/ES2331970T3/es active Active
- 2006-11-10 EP EP06804388A patent/EP1962887B1/de active Active
- 2006-11-10 JP JP2008546020A patent/JP2009520696A/ja active Pending
- 2006-11-10 RU RU2008130413/15A patent/RU2008130413A/ru not_active Application Discontinuation
- 2006-11-10 CN CNA2006800486507A patent/CN101365477A/zh active Pending
-
2008
- 2008-06-19 IL IL192349A patent/IL192349A0/en unknown
- 2008-07-17 NO NO20083191A patent/NO20083191L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Billipp et al. | Tuft cell-derived acetylcholine promotes epithelial chloride secretion and intestinal helminth clearance | |
| Forbes et al. | Liver fibrogenic cells | |
| Dolmatova et al. | Cardiomyocyte ATP release through pannexin 1 aids in early fibroblast activation | |
| Lei et al. | Hic-5 deficiency attenuates the activation of hepatic stellate cells and liver fibrosis through upregulation of Smad7 in mice | |
| Sharma et al. | Pannexin-1 channels on endothelial cells mediate vascular inflammation during lung ischemia-reperfusion injury | |
| Campanholle et al. | Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis | |
| Chung et al. | Hepatic expression of Sonic Hedgehog induces liver fibrosis and promotes hepatocarcinogenesis in a transgenic mouse model | |
| Tsukui et al. | Qualitative rather than quantitative changes are hallmarks of fibroblasts in bleomycin-induced pulmonary fibrosis | |
| Ciminieri et al. | IL-1β induces a proinflammatory fibroblast microenvironment that impairs lung progenitors’ function | |
| Liu et al. | Ticagrelor attenuates myocardial ischaemia–reperfusion injury possibly through downregulating galectin‐3 expression in the infarct area of rats | |
| Li et al. | BML-111 attenuates hemorrhagic shock-induced acute lung injury through inhibiting activation of mitogen-activated protein kinase pathway in rats | |
| HRP20120743T1 (hr) | Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja | |
| JP2013503110A5 (enExample) | ||
| Rui et al. | Urinary trypsin inhibitor attenuates seawater-induced acute lung injury by influencing the activities of nuclear factor-ĸB and its related inflammatory mediators | |
| JP2008013542A5 (enExample) | ||
| Novo et al. | Hepatic myofibroblasts and fibrogenic progression of chronic liver diseases | |
| Di Carmine et al. | The role of interleukin-33 in organ fibrosis | |
| Mathew et al. | Pulmonary artery hypertension: caveolin-1 and eNOS interrelationship: a new perspective | |
| UY32969A (es) | Polipéptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas | |
| Yang et al. | Membrane translocation of IL-33 receptor in ventilator induced lung injury | |
| JP2010502979A5 (enExample) | ||
| Lin et al. | Pygo1 regulates pathological cardiac hypertrophy via a β-catenin-dependent mechanism | |
| Chi et al. | Knockdown of myeloid differentiation protein-2 reduces acute lung injury following orthotopic autologous liver transplantation in a rat model | |
| Coll-Bonfill et al. | Slug is increased in vascular remodeling and induces a smooth muscle cell proliferative phenotype | |
| Minamino et al. | Adhesion of platelets through thromboxane A2 receptor signaling facilitates liver repair during acute chemical-induced hepatotoxicity |